NK 001 - EMERCell
Alternative Names: NK-001 - EMERCellLatest Information Update: 26 Sep 2022
At a glance
- Originator EMERCell
- Developer EMERCell; Onward Therapeutics
- Class Antineoplastics; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Acute myeloid leukaemia; Lymphoma
Most Recent Events
- 26 Sep 2022 Emercell plans a clinical trial for lymphoma (Second-line therapy or greater) in France in 2023
- 23 Jun 2021 EMERCell plans preclinical studies in solid tumour (Combination therapy) (Parenteral) (EMERCell website, June 2021)
- 14 Jun 2021 Preclinical trials in Lymphoma (Combination therapy) in France (Parenteral) prior to June 2021 (EMERcell website, June 2021)